MethylGene Inc. is a Canada-based biopharmaceutical company focused on the discovery, development and commercialization of therapeutics for cancer. The Company’s product candidates include MGCD265, an oral, multi-targeted kinase inhibitor targeting the c-Met, VEGF, Tie-two and Ron receptor tyrosine kinases that is in two Phase I clinical trials for solid tumor cancers; MGCD290, a fungal hos2 (HDAC) inhibitor being developed in combination with fluconazole for fungal infections, and MGCD0103, an oral, isoform-selective HDAC inhibitor which has been in multiple clinical trials for solid tumors and hematological malignancies. EVP-0334, a potential cognition enhancing agent, is in a Phase I study sponsored by EnVivo Pharmaceuticals Inc. MethylGene also has a collaboration with Otsuka Pharmaceutical Co. Ltd. for application in ocular diseases using the Company’s kinase inhibitor chemistry.